Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.

Dworkin M, Mehan W, Niemierko A, Kamran SC, Lamba N, Dietrich J, Martinez-Lage M, Oh KS, Batchelor TT, Wen PY, Loeffler JS, Shih HA.

J Neurooncol. 2018 Nov 28. doi: 10.1007/s11060-018-03063-1. [Epub ahead of print]

PMID:
30488294
2.

Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma.

Bronk JK, Guha-Thakurta N, Allen PK, Mahajan A, Grosshans DR, McGovern SL.

Clin Transl Radiat Oncol. 2018 Jan 12;9:30-34. doi: 10.1016/j.ctro.2018.01.002. eCollection 2018 Feb.

3.

Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.

Boxerman JL, Ellingson BM, Jeyapalan S, Elinzano H, Harris RJ, Rogg JM, Pope WB, Safran H.

Am J Clin Oncol. 2017 Jun;40(3):228-234. doi: 10.1097/COC.0000000000000156.

PMID:
25436828
4.

Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.

Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.

Radiat Oncol. 2013 Feb 20;8:38. doi: 10.1186/1748-717X-8-38.

5.

Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.

Chaskis C, Neyns B, Michotte A, De Ridder M, Everaert H.

Surg Neurol. 2009 Oct;72(4):423-8. doi: 10.1016/j.surneu.2008.09.023. Epub 2009 Jan 15.

PMID:
19150114
6.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
7.

Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence.

Radbruch A, Fladt J, Kickingereder P, Wiestler B, Nowosielski M, Bäumer P, Schlemmer HP, Wick A, Heiland S, Wick W, Bendszus M.

Neuro Oncol. 2015 Jan;17(1):151-9. doi: 10.1093/neuonc/nou129. Epub 2014 Jul 18.

8.

Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.

Rowe LS, Butman JA, Mackey M, Shih JH, Cooley-Zgela T, Ning H, Gilbert MR, Smart DK, Camphausen K, Krauze AV.

J Neurooncol. 2018 May 16. doi: 10.1007/s11060-018-2855-z. [Epub ahead of print]

PMID:
29767308
9.

Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.

Grosu AL, Weber WA, Franz M, Stärk S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C.

Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):511-9.

PMID:
16168843
10.

Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review.

Hafazalla K, Sahgal A, Jaja B, Perry JR, Das S.

Oncotarget. 2018 Sep 14;9(72):33623-33633. doi: 10.18632/oncotarget.25890. eCollection 2018 Sep 14.

11.

Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.

Paravati AJ, Heron DE, Landsittel D, Flickinger JC, Mintz A, Chen YF, Huq MS.

J Neurooncol. 2011 Aug;104(1):339-49. doi: 10.1007/s11060-010-0499-8. Epub 2010 Dec 22.

12.

Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.

van West SE, de Bruin HG, van de Langerijt B, Swaak-Kragten AT, van den Bent MJ, Taal W.

Neuro Oncol. 2017 May 1;19(5):719-725. doi: 10.1093/neuonc/now194.

13.

Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide.

McTyre E, Lucas JT, Helis C, Farris M, Soike M, Mott R, Laxton AW, Tatter SB, Lesser GJ, Strowd RE, Lo HW, Debinski W, Chan MD.

Am J Clin Oncol. 2018 Aug;41(8):813-819. doi: 10.1097/COC.0000000000000380.

PMID:
28301347
14.

Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management.

Ou SH, Klempner SJ, Azada MC, Rausei-Mills V, Duma C.

Lung Cancer. 2015 Jun;88(3):355-9. doi: 10.1016/j.lungcan.2015.03.022. Epub 2015 Mar 30.

PMID:
25882777
15.

Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma.

Haque W, Verma V, Butler EB, Teh BS.

J Neurooncol. 2017 Jun;133(2):369-375. doi: 10.1007/s11060-017-2443-7. Epub 2017 Apr 21.

PMID:
28432588
16.

Pseudoprogression in high-grade glioma.

Knudsen-Baas KM, Moen G, Fluge Ø, Storstein A.

Acta Neurol Scand Suppl. 2013;(196):31-7. doi: 10.1111/ane.12047. Review. Erratum in: Acta Neurol Scand Suppl. 2013 Mar;127(3):e17.

PMID:
23190289
17.

Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.

Tsien C, Galbán CJ, Chenevert TL, Johnson TD, Hamstra DA, Sundgren PC, Junck L, Meyer CR, Rehemtulla A, Lawrence T, Ross BD.

J Clin Oncol. 2010 May 1;28(13):2293-9. doi: 10.1200/JCO.2009.25.3971. Epub 2010 Apr 5.

18.

Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.

Pinho MC, Polaskova P, Kalpathy-Cramer J, Jennings D, Emblem KE, Jain RK, Rosen BR, Wen PY, Sorensen AG, Batchelor TT, Gerstner ER.

Oncologist. 2014 Jan;19(1):75-81. doi: 10.1634/theoncologist.2013-0101. Epub 2013 Dec 5.

19.

Population-based study of pseudoprogression after chemoradiotherapy in GBM.

Roldán GB, Scott JN, McIntyre JB, Dharmawardene M, de Robles PA, Magliocco AM, Yan ES, Parney IF, Forsyth PA, Cairncross JG, Hamilton MG, Easaw JC.

Can J Neurol Sci. 2009 Sep;36(5):617-22.

PMID:
19831132
20.

The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.

Sher DJ, Henson JW, Avutu B, Hochberg FH, Batchelor TT, Martuza RL, Barker FG 2nd, Loeffler JS, Chakravarti A.

J Neurooncol. 2008 May;88(1):43-50. doi: 10.1007/s11060-008-9530-8. Epub 2008 Jan 30.

Supplemental Content

Support Center